These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 16724964)

  • 1. Proceedings of the TCT: questions surround antithrombotic therapy in coronary DES implantation.
    White J
    J Interv Cardiol; 2006 Jun; 19(3):232-5. PubMed ID: 16724964
    [No Abstract]   [Full Text] [Related]  

  • 2. Proceedings of the TCT: duration of antiplatelet therapy survey.
    Kahn J
    J Interv Cardiol; 2006 Jun; 19(3):236. PubMed ID: 16724965
    [No Abstract]   [Full Text] [Related]  

  • 3. Is the end of restenosis the beginning of a new era?
    Moses JW
    Ital Heart J; 2004 Feb; 5(2):81-4. PubMed ID: 15086136
    [No Abstract]   [Full Text] [Related]  

  • 4. TCT Daily: safety profile of drug-eluting stents similar to bare-metal stents: lower restenosis rates associated with DES.
    Kahn J
    J Interv Cardiol; 2007 Feb; 20(1):30-1. PubMed ID: 17300395
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications.
    Lüscher TF; Steffel J; Eberli FR; Joner M; Nakazawa G; Tanner FC; Virmani R
    Circulation; 2007 Feb; 115(8):1051-8. PubMed ID: 17325255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-eluting stents in total coronary occlusions: another piece of the puzzle solved?
    Dzavik V
    Am Heart J; 2006 Nov; 152(5):807-9. PubMed ID: 17070136
    [No Abstract]   [Full Text] [Related]  

  • 7. Very late [corrected] thrombosis of a sirolimus-eluting stent.
    Henderson D; Gunalingam B
    Catheter Cardiovasc Interv; 2006 Sep; 68(3):406-8. PubMed ID: 16892439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unrestricted use of drug-eluting stents compared with bare-metal stents in routine clinical practice: findings from the National Heart, Lung, and Blood Institute Dynamic Registry.
    Abbott JD; Voss MR; Nakamura M; Cohen HA; Selzer F; Kip KE; Vlachos HA; Wilensky RL; Williams DO
    J Am Coll Cardiol; 2007 Nov; 50(21):2029-36. PubMed ID: 18021868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Percutaneous treatment of coronary bifurcations: lesion preparation before provisional bare metal stenting and subsequent immunosuppression with oral prednisone. The IMPRESS-Y study.
    Ribichini F; Ferrero V; Rognoni A; Marino P; Brunelleschi S; Vassanelli C
    J Interv Cardiol; 2007 Apr; 20(2):114-21. PubMed ID: 17391219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coronary artery stents: Part I. Evolution of percutaneous coronary intervention.
    Newsome LT; Kutcher MA; Royster RL
    Anesth Analg; 2008 Aug; 107(2):552-69. PubMed ID: 18633035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coronary complications of percutaneous coronary intervention: a practical approach to the management of abrupt closure.
    Klein LW
    Catheter Cardiovasc Interv; 2005 Mar; 64(3):395-401. PubMed ID: 15736213
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical outcomes after multilesion percutaneous coronary intervention: comparison between exclusive and selective use of drug-eluting stents.
    Bertrand OF; Faurie B; Larose E; Nguyen CM; Gleeton O; Déry JP; Noël B; Proulx G; Roy L; Costerousse O; De Larochellière R; Rodés-Cabau J
    J Invasive Cardiol; 2008 Mar; 20(3):99-104. PubMed ID: 18316823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
    Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C
    J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents.
    Whan Lee C; Kim SH; Suh J; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):594-8. PubMed ID: 18311841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Focal in-stent restenosis and in-stent thrombosis within the same bare-metal stent 5 years after deployment in a saphenous vein graft.
    Ponnuthurai FA; van Gaal WJ; Channon KM
    J Invasive Cardiol; 2007 Dec; 19(12):E369-71. PubMed ID: 18180530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stent thrombosis in the era of drug eluting stents.
    Kawaguchi R; Angiolillo DJ; Futamatsu H; Suzuki N; Bass TA; Costa MA
    Minerva Cardioangiol; 2007 Apr; 55(2):199-211. PubMed ID: 17342038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TCT Daily: ESTROFA: late thrombosis not increased in DES patients: Spanish registry of drug-eluting stents shows STEMI, LAD artery lesions, significant risk factors.
    Kahn J
    J Interv Cardiol; 2007 Feb; 20(1):32. PubMed ID: 17300396
    [No Abstract]   [Full Text] [Related]  

  • 18. In-stent thrombosis after discontinuation of antiplatelet therapy 2 years after DES implantation: a case report.
    De Luca G; Carbone G; Maione A; Gregorio G
    Int J Cardiol; 2007 Apr; 116(3):399-400. PubMed ID: 17258334
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug-eluting stent in saphenous vein graft lesions.
    Kornowski R
    Catheter Cardiovasc Interv; 2008 Jun; 71(7):894-5. PubMed ID: 18498140
    [No Abstract]   [Full Text] [Related]  

  • 20. A monk's prayer: O Lord what is the answer to in-stent restenosis? Commentary on the TRAPIST Study.
    Murphy JG
    Eur Heart J; 2001 Oct; 22(20):1847-9. PubMed ID: 11601833
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.